Unlike animals, plants do not possess an adaptive immune system with antibodies or T cells to fight viral infections. Instead ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

Before a prostate biopsy is performed, various preliminary screening procedures are typically conducted. These include a ...

Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...

Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

Aqemia announces it is broadening and accelerating its computational platform to target RNAs using its physics-enabled ...

A research group led by Gian Gaetano Tartaglia, Principal Investigator at the Italian Institute of Technology (IIT), ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

There is an urgent need for precision immunotherapy strategies that simultaneously target both tumor cells and immune cells ...